Tara Caitlin Boute

Ms. Tara Caitlin Boute


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
TBTara Caitlin Boute
Tara Caitlin Boute
HSHidde Swartjes
Hidde Swartjes
MGMarjolein J.E. Greuter
Marjolein J.E. Greuter
MEMarloes A.G. Elferink
Marloes A.G. Elferink
RERik van Eekelen
Rik van Eekelen
VCVeerle M.H. Coupe
Veerle M.H. Coupe
Real-world data are necessitated to counsel patients about the risk for recurrent disease after curative treatment of colorectal cancer. This study provided a population-based overview of the epidemiology of recurrent disease in patients with surgically resected stage II/III colorectal cancer. Patients diagnosed with stage II/III primary colorectal cancer between July and December 2015 were selected from the Netherlands Cancer Registry (N = 3,762). Cumulative incidence of recurrent disease was estimated, and multivariable competing risk regression was used to identify risk factors for recurrent disease in patients with primary colon and rectal cancer. Moreover, overall survival (OS) after diagnosis of recurrent colorectal cancer was estimated. Median clinical follow-up was 58 months (Q1–Q3: 22–62). Five-year cumulative incidence of recurrent disease was 21.6% [95% confidence interval (CI): 20.0–23.2] and 30.0% (95% CI: 28.3–33.5) for patients with primary colon and rectal cancer, respectively. Stage III disease and incomplete resection margin in patients with primary colon cancer and extramural vascular invasion in patients with primary rectal cancer were strongly (HR ≥ 2) associated with recurrent disease. Median OS of patients with distant, locoregional, or the synchronous combination of distant and locoregional recurrent disease was 29, 27, and 13 months, respectively (P < 0.001). Patients with distant recurrences limited to liver or lung showed a median OS of 46 and 48 months, respectively. The incidence of recurrent disease was higher in patients with rectal cancer than in patients with colon cancer, predominantly due to higher rates of distant recurrences. OS after recurrent disease was impaired, but subgroups of patients diagnosed with recurrent disease limited to one site showed statistically significantly longer OS. Significance: Population-based data on recurrent colorectal cancer are rare, but crucial for counseling patients and their physicians. This large nationwide, population-based study provides an up-to-date overview of the epidemiology of recurrent disease in patients with stage II and III primary colon and rectal cancer treated with surgical resection.

27 February 2025 in Cancer Medicine
Verified
Journal Article
Open access
TBTara Caitlin Boute
Tara Caitlin Boute
RERik van Eekelen
Rik van Eekelen
MEMarloes A. G. Elferink
Marloes A. G. Elferink
LBLissenberg Witte Birgit
Lissenberg Witte Birgit
JWJohannes H. W. de Wilt
Johannes H. W. de Wilt
VCVeerle M. H. Coupé
Veerle M. H. Coupé
Introduction: After colorectal cancer (CRC) treatment, patients undergo five‐year follow‐up involving carcinoembryonic antigen (CEA) tests, imaging, and colonoscopies. This retrospective cohort study explores adherence to the CRC follow‐up guideline in the Netherlands until 2021 and its association with treatment of recurrences with curative intent.Methods: Stage II/III CRC patients with recurrent disease within 3 years after diagnosis were selected from the Netherlands Cancer Registry (n = 430). Adherence to CEA tests, imaging, and colonoscopy was classified as ‘according to/more follow‐up’ or ‘less follow‐up’ than recommended. Logistic regression analyses examined factors associated with receiving less follow‐up and the relationship between ‘follow‐up adherence’ and ‘treatment with curative intent’, potentially mediated by ‘mode of detection’ (symptomatically vs. routine test).Results: In total, 18.3% patients had fewer CEA tests, 41.4% fewer imaging, and 56.1% fewer colonoscopies than recommended. Factors associated with fewer follow‐up moments were tumor localization, age (≥ 75 years), comorbidities, tumor differentiation and adjuvant chemotherapy. Patients receiving fewer CEA tests faced 4.8 times higher odds (95% CI: 2.9–8.1) of symptom‐detected recurrence and were less likely to be curatively treated (OR = 0.5; 95% CI: 0.3–0.9). Mediation analysis indicated a significant average causal mediation effect (p = 0.003), emphasizing the mediating role of mode of detection. Receiving fewer imaging and colonoscopies showed insignificant total effects on treatment with curative intent.Conclusion: Our findings offer insights into follow‐up adherence, detection mode, and treatment with curative intent. The discovery that adherence was highest for CEA, along with the correlation between CEA adherence and treatment with curative intent, aligns with the recent adaptation of guidelines emphasizing CEA measurement over imaging.


29 February 2024
Verified
Other
Open access
TBTara Caitlin Boute
Tara Caitlin Boute
HSHidde Swartjes
Hidde Swartjes
MGMarjolein J.E. Greuter
Marjolein J.E. Greuter
MEMarloes A.G. Elferink
Marloes A.G. Elferink
RERik van Eekelen
Rik van Eekelen
VCVeerle M.H. Coupe
Veerle M.H. Coupe
Univariable and multivariable competing risk regression output for the risk of recurrent disease in colon cancer patients


29 February 2024
Verified
Other
Open access
TBTara Caitlin Boute
Tara Caitlin Boute
HSHidde Swartjes
Hidde Swartjes
MGMarjolein J.E. Greuter
Marjolein J.E. Greuter
MEMarloes A.G. Elferink
Marloes A.G. Elferink
RERik van Eekelen
Rik van Eekelen
VCVeerle M.H. Coupe
Veerle M.H. Coupe
Real-world data are necessitated to counsel patients about the risk for recurrent disease after curative treatment of colorectal cancer. This study provided a population-based overview of the epidemiology of recurrent disease in patients with surgically resected stage II/III colorectal cancer.Patients diagnosed with stage II/III primary colorectal cancer between July and December 2015 were selected from the Netherlands Cancer Registry (N = 3,762). Cumulative incidence of recurrent disease was estimated, and multivariable competing risk regression was used to identify risk factors for recurrent disease in patients with primary colon and rectal cancer. Moreover, overall survival (OS) after diagnosis of recurrent colorectal cancer was estimated.Median clinical follow-up was 58 months (Q1–Q3: 22–62). Five-year cumulative incidence of recurrent disease was 21.6% [95% confidence interval (CI): 20.0–23.2] and 30.0% (95% CI: 28.3–33.5) for patients with primary colon and rectal cancer, respectively. Stage III disease and incomplete resection margin in patients with primary colon cancer and extramural vascular invasion in patients with primary rectal cancer were strongly (HR ≥ 2) associated with recurrent disease. Median OS of patients with distant, locoregional, or the synchronous combination of distant and locoregional recurrent disease was 29, 27, and 13 months, respectively (P < 0.001). Patients with distant recurrences limited to liver or lung showed a median OS of 46 and 48 months, respectively. The incidence of recurrent disease was higher in patients with rectal cancer than in patients with colon cancer, predominantly due to higher rates of distant recurrences. OS after recurrent disease was impaired, but subgroups of patients diagnosed with recurrent disease limited to one site showed statistically significantly longer OS.Significance:Population-based data on recurrent colorectal cancer are rare, but crucial for counseling patients and their physicians. This large nationwide, population-based study provides an up-to-date overview of the epidemiology of recurrent disease in patients with stage II and III primary colon and rectal cancer treated with surgical resection.